HomeTOP STORIESArrowhead rises as FDA approves lead drug for rare disorder Arrowhead rises as FDA approves lead drug for rare disorder By rogerjudd November 18, 2025 FacebookTwitterPinterestWhatsApp Post Content Previous articleLukoil’s suitor list grows to include Exxon – BloombergNext articleblueharbor bank declares $0.25 dividend latest articles Thursday’s Economic Calendar Nvidia leads semiconductor stocks higher Williams-Sonoma raises operating margin outlook to 17.8%-18.1% as AI, retail investments drive Q4 optimism Nvidia declares $0.01 dividend NVIDIA targets $65B Q4 revenue and $0.5T Blackwell & Rubin sales through 2026 while expanding AI infrastructure partnerships Saudi Arabia, Once Shunned, Has Corporate Titans Swooning for Deals explore more Thursday’s Economic Calendar Nvidia leads semiconductor stocks higher Williams-Sonoma raises operating margin outlook to 17.8%-18.1% as AI, retail investments drive Q4 optimism Nvidia declares $0.01 dividend NVIDIA targets $65B Q4 revenue and $0.5T Blackwell & Rubin sales through 2026 while expanding AI infrastructure partnerships Saudi Arabia, Once Shunned, Has Corporate Titans Swooning for Deals
